[Some opportunities for the application of the drug mycosyst (preliminary communication)].
The colpitis is one of the most frequent gynaecological disease. The different methods of treatment of colpitis are a matter of discussion in many specialized studies. The aim of our retrospective study was to evaluate the therapeutic effects of Mycosyst (Fluconazol), produced by the pharmaceutical company Gedeon Richter (Budapest, Hungary), on women with acute fungal colpitis. The experience dated from about eight months (April--December 2002) with 27 patient with anamnestic, clinical, microscopic and microbiological data of fungal colpitis. Women were divided into two groups: 16 patients with diagnosed fungal colpitis at the time of interruption of pregnancy and 11 patients with this complaints not related to pregnancy. The therapeutic scheme is 150 mg Mycosyst as a single dose. The subjective complaints began to disappear 48 hours after the administration and were completely eliminated in almost all cases four days later. The medicine has a very fast effect on pruritus, erythema and urinary complaints, and a little bit slower influences the vaginal fluor. Some good pharmacodynamic and pharmacokinetic parameters of Mycosyst are: fast and complete absorption in gastrointestinal tract, long plasma life, elimination by the kidneys without being metabolized, doesn't affect the plasma concentration of steroids and testosterone, high and long terming concentration in each stratum of skin, nails, vaginal secretion and saliva. Our conclusion is that Mycosyst is reliable, easily applied broad-spectrum azol antifungal. The single dose of 150 mg is sufficient for treatment of acute fungal colpitis in almost 90%. The medicine is comparatively cheap and accessible.